Skip to main content
. 2018 Sep 17;99(6):1580–1582. doi: 10.4269/ajtmh.18-0387

Figure 2.

Figure 2.

(A) Ivermectin treatment timeline demonstrating relationship between days of subcutaneous and nasogastric ivermectin doses, plasma ivermectin 1Ba concentration, and bronchial larval motility. (B) Postmortem tissue analysis of ivermectin 1Ba concentration.